AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-α in Jurkat leukemic cells
- 6 November 2003
- journal article
- Published by Springer Nature in Oncogene
- Vol. 22 (50), 8187-8194
- https://doi.org/10.1038/sj.onc.1206963
Abstract
NF-B transcription factors promote survival in numerous cell types via induction of antiapoptotic genes. Pharmacological blockade of the IKK2 kinase with AS602868, a specific inhibitor that competes with ATP binding, prevented TNF--induced NF-B activation in Jurkat leukemic T cells. While TNF- by itself had no effect on Jurkat survival, the addition of AS602868 induced cell death, visualized by DNA fragmentation and sub-G1 analysis. A disruption of the mitochondrial potential followed by activation of caspases 9 and 3 was observed in cells treated by the combination TNF-+AS602868. Quantitative real-time PCR demonstrated that AS602868 prevented TNF- induction of the antiapoptotic genes coding for c-IAP-2, Bclx, Bfl-1/A1 and Traf-1. The use of a specific IKK2 inhibitor appears, therefore, as an interesting pharmaceutical strategy to increase the cell's sensitivity towards apoptotic effectors.Keywords
This publication has 34 references indexed in Scilit:
- NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasiaNature, 2003
- Nuclear transcription factor-κB as a target for cancer drug developmentLeukemia, 2002
- IAP proteins: blocking the road to death's doorNature Reviews Molecular Cell Biology, 2002
- TNF-R1 Signaling: A Beautiful PathwayScience, 2002
- NF-κB in cancer: from innocent bystander to major culpritNature Reviews Cancer, 2002
- NF-κB at the crossroads of life and deathNature Immunology, 2002
- Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-κB inhibitionOncogene, 2000
- The Hallmarks of CancerCell, 2000
- Aberrant rel/nfkb genes and activity in human cancerOncogene, 1999
- Activators and target genes of Rel/NF-κB transcription factorsOncogene, 1999